Navidea Biopharmaceuticals (NYSE:NAVB) Now Covered by Analysts at StockNews.com

Analysts at StockNews.com started coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB) in a report issued on Saturday. The brokerage set a “sell” rating on the stock.

Navidea Biopharmaceuticals Stock Performance

Shares of NYSE NAVB opened at $0.04 on Friday. The stock has a market cap of $3.81 million, a P/E ratio of -0.63 and a beta of 1.13. Navidea Biopharmaceuticals has a twelve month low of $0.02 and a twelve month high of $0.31. The stock has a 50 day moving average of $0.04 and a two-hundred day moving average of $0.05.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Navidea Biopharmaceuticals stock. State Street Corp lifted its holdings in shares of Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) by 1,631.1% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 412,743 shares of the company’s stock after buying an additional 388,900 shares during the period. State Street Corp owned approximately 1.18% of Navidea Biopharmaceuticals worth $38,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 0.01% of the company’s stock.

Navidea Biopharmaceuticals Company Profile

Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases.